Healios K.K (TYO:4593) plans to submit a conditional and time-limited approval application in Japan for HLCM051, following positive results from the Phase 2 ONE-BRIDGE study in Japan and the MUST-ARDS study in the US and UK.
The upcoming global Phase 3 REVIVE-ARDS trial in the US will serve as a confirmatory study, according to its Thursday bourse filing.
A portion of the data for this application, highlighting the efficacy of HLCM051 in extending ventilator-free days and reducing mortality, has been published in the journal Regenerative Therapy.
This publication, led by Dr. Kazuya Ichikado, boosts the credibility of the submission.
Price (JPY): $278.00, Change: $+2.0, Percent Change: +0.72%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.